Association Between Bone Mineral Density and Autoantibodies in Patients With Rheumatoid Arthritis

Abstract

The presence of ACPAs is associated with significantly lower BMD at baseline, but not with greater BMD loss over time in treated RA patients. These results suggest that ACPAs alone do not appear to contribute to bone loss after disease onset when disease activity is well-managed.